BioCentury
ARTICLE | Politics, Policy & Law

Congress relying on flawed model to set drug pricing policy

CBO model ignores impact on preclinical biotechs, underestimates effects of price controls on drug development

August 28, 2021 12:47 AM UTC


Access this Article